Search

everythinglearnresearchcommunity

for

Search:↓

Researchers should follow the FACE-Q User's Guide for accurate results.

Gender differences affect allergy prevalence, severity, and response to environmental toxins, with women often more affected than men.

Women experience more side effects and have worse blood pressure control from hypertension treatments than men, despite using different medications.

SHA lowers the hairline quickly and patients are usually happy with the results if they are good candidates.

Dermatologists are crucial in providing personalized care for patients with sex development differences.

Aesthetic care should align physical changes with mental well-being using a comprehensive, multidisciplinary approach.

The Endotine Forehead-mini effectively lowers the hairline with lasting results and minimal risks.

Oral estradiol works for many transgender women but needs personalized dosing and monitoring.

Gender-affirming hormone therapy affects health risks and requires careful management, especially as transgender individuals age.

Testosterone treatment in transgender teens can worsen acne, requiring careful treatment due to mental health and medication side effects.

Oocyte retrieval is possible for transgender men on testosterone therapy without affecting fertility outcomes.

Transgender women can still get testicular cancer, so proper screening is important.

Hair transplantation can help transgender patients affirm their gender identity.

Young transgender, gender diverse, and nonbinary people on spironolactone have a low risk of high potassium, so frequent monitoring may not be needed.

Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.

Testosterone increases hair growth and acne in transgender men.

Ensure respectful and inclusive care for transgender and gender-diverse patients during surgery.

Hormone therapy affects cancer risks in transgender individuals differently than in cisgender people, and more research is needed to understand these risks and improve cancer screening guidelines.

Most transgender adolescents continued hormone treatment, with few stopping due to reasons other than returning to their birth gender.

Transgender and nonbinary individuals experience hair loss, with transmen on testosterone seeing more severe hair loss, while feminizing hormones may stabilize hair loss in transwomen.

Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.

Doctors are preparing to potentially perform uterus transplants in transgender women, considering technical, hormonal, and ethical factors.

Transgender individuals face more barriers and less autonomy in surgical body modifications compared to cisgender individuals.

Psoriasis rates in transgender people are similar to the general population, but hormone therapy might affect it.

Transgender women on estrogen therapy can develop melasma and need proper skin care.

Masculinizing hormone therapy increases the risk of hair loss in transgender and gender-diverse patients.

Transgender individuals may face specific skin issues during gender-affirming treatments, needing personalized care.

Transgender men on testosterone therapy need ongoing gynecologic care due to potential cancer risks.

Hormone therapy in transgender individuals can increase acne and affect hair growth and loss.

Spironolactone and finasteride are equally effective for hirsutism in transgender women.